STELLAR
2023
Sotatercept for the Treatment of Pulmonary Arterial Hypertension
In 323 patients with pulmonary arterial hypertension, sotatercept added to background therapy improved 6-minute walk distance compared with placebo.
Result
Primary endpoint: Change in 6-minute walk distance at 24 weeks
+40.8 m placebo-corrected; clinical worsening or death HR 0.16.
- Subtopic
- Activin signalling
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Hoeper MM, et al. N Engl J Med. 2023;388(16):1478-1490.doi 10.1056/NEJMoa2213558
Discussion & critique
An activin-signalling inhibitor, a mechanism beyond vasodilators. Led to approval; ZENITH later showed a mortality-relevant benefit in high-risk PAH.